NasdaqGS:GBT 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Jun 22	235	-322	303	227
31 Mar 22	211	-310	283	214
31 Dec 21	195	-303	267	212
30 Sep 21	180	-277	248	194
30 Jun 21	165	-266	234	184
31 Mar 21	149	-249	222	166
31 Dec 20	124	-248	211	155
30 Sep 20	85	-282	196	179
30 Jun 20	48	-286	171	178
31 Mar 20	16	-291	147	180
31 Dec 19	2	-267	117	175
30 Sep 19	0	-220	88	146
30 Jun 19	0	-199	71	140
31 Mar 19	0	-182	57	136
31 Dec 18	0	-174	51	131
30 Sep 18	0	-166	46	127
30 Jun 18	0	-152	43	114
31 Mar 18	0	-135	38	100
31 Dec 17	0	-117	31	88
30 Sep 17	0	-103	27	76
30 Jun 17	0	-95	24	72
31 Mar 17	0	-89	22	66
31 Dec 16	0	-82	20	61
30 Sep 16	0	-71	20	52
30 Jun 16	0	-65	16	49
31 Mar 16	0	-58	13	43

양질의 수익: GBT 은(는) 현재 수익성이 없습니다.

이익 마진 증가: GBT 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: GBT 은(는) 수익성이 없으며 지난 5년 동안 연간 20.1% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 GBT 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: GBT 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: GBT 현재 수익성이 없기 때문에 마이너스 자본 수익률( -272.44% )을 갖습니다.

Global Blood Therapeutics 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Global Blood Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2021 earnings: EPS exceeds analyst expectations

Global Blood Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Third quarter 2021 earnings released: US$1.13 loss per share (vs US$0.97 loss in 3Q 2020)

Recent updates

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from NASDAQ Composite Index

Pfizer Inc. (NYSE:PFE) completed the acquisition of Global Blood Therapeutics, Inc. (NasdaqGS:GBT) from a group of shareholders.

Executive Vice President of Operations exercised options to buy US$2.0m worth of stock.

Global Blood Therapeutics expects to complete Pfizer deal in early October

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

CFO & Principal Accounting Officer recently sold US$1.9m worth of stock

CFO & Principal Accounting Officer notifies of intention to sell stock

Pfizer said to have had bidding war with Johnson & Johnson for Global Blood

Executive Vice President of Operations recently sold US$314k worth of stock

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Pfizer Inc. (NYSE:PFE) entered into a definitive agreement to acquire Global Blood Therapeutics, Inc. (NasdaqGS:GBT) for $5 billion.

Price target increased to US$66.03

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics

Pfizer Reportedly in Advanced Talks to Buy Global Blood Therapeutics for $5 Billion

CFO & Principal Accounting Officer exercised options and sold US$69k worth of stock

Global Blood Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

MHRA Grants Marketing Authorization for Global Blood Therapeutics, Inc.'s Oxbryta (Voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older

Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil

Global Blood Therapeutics, Inc. Initiates Phase 2/3 Clinical Trial of GBT601 in Patients with Sickle Cell Disease

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Independent Director notifies of intention to sell stock

Global Blood Therapeutics: Powerhouse Of The Future

Global Blood Therapeutics, Inc. Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta (Voxelotor) in Sickle Cell Disease

Global Blood Therapeutics, Inc.'s Inclacumab and GBT601 Receive U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for the Treatment of Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Blood Therapeutics: Hitting A Growth Inflection

Chief Commercial Officer exercised options and sold US$54k worth of stock

No longer forecast to breakeven

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

Consensus EPS estimates fall by 23%

Full year 2021 earnings: EPS exceeds analyst expectations

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Global Blood Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

CFO & Principal Accounting Officer exercised options and sold US$132k worth of stock

CFO & Principal Accounting Officer exercised options and sold US$132k worth of stock

Global Blood Therapeutics, Inc. Announces Positive Early Access to Medicines Scheme Scientific Opinion

Global Blood Therapeutics, Inc. announces Oxbryta® (voxelotor) tablets for oral suspension

Forecast to breakeven in 2024

Global Blood Therapeutics: Revisiting A Stellar Grower

Global Blood Therapeutics, Inc. Receives Positive CHMP Opinion for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Aged 12 Years and Older

Global Blood Therapeutics, Inc. Presents Positive Results from Phase 1 Study of Gbt021601 in Patients with Sickle Cell Disease and Healthy Volunteers At ASH Annual Meeting and Exposition

GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition

IBI Research On Global Blood Therapeutics: Galvanized For Growth

Third quarter 2021 earnings released: US$1.13 loss per share (vs US$0.97 loss in 3Q 2020)

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Global Blood Therapeutics: It Might Be Time To Buy The Dip

Chief Commercial Officer exercised options and sold US$57k worth of stock

Independent Director recently sold US$145k worth of stock

Global Blood Therapeutics, Inc. Announces the U.S. Food and Drug Administration Accepts for Priority Review Supplemental New Drug Application for Oxbryta (Voxelotor)

President exercised options and sold US$140k worth of stock

Global Blood Therapeutics: Attempting To Classify The Investment

Second quarter 2021 earnings released: US$1.12 loss per share (vs US$0.86 loss in 2Q 2020)

CFO & Principal Accounting Officer exercised options and sold US$119k worth of stock

Global Blood Therapeutics, Inc. Provides Regulatory and Pipeline Updates in Sickle Cell Disease

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Global Blood Therapeutics, Inc.(NasdaqGS:GBT) dropped from Russell Midcap Growth Index

Independent Director exercised options and sold US$59k worth of stock

Global Blood Therapeutics, Inc. Announces Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine Designation in the UK

Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why

Global Blood Therapeutics, Inc. Announces New Data from the Phase 2a HOPE-KIDS 1 Study

Global Blood Therapeutics announces employment inducement grants

Consensus EPS estimates fall to -US$4.55

Global Blood Therapeutics: Increasing Specialization In SCD

Global Blood Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter of 2021

First quarter 2021 earnings released: US$1.21 loss per share (vs US$1.20 loss in 1Q 2020)

Chief Commercial Officer exercised options and sold US$64k worth of stock

Global Blood Therapeutics, Inc. Appoints Alexis A. Thompson to the Board as A Class I Director